ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -23 مورد

Atropine (systemic): Drug information

Atropine (systemic): Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Atropine (systemic): Patient drug information" and "Atropine (systemic): Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • AtroPen [DSC]
Pharmacologic Category
  • Anticholinergic Agent;
  • Antidote;
  • Antispasmodic Agent, Gastrointestinal
Dosing: Adult

Dosage guidance:

Safety: IV doses ≤0.25 mg have been associated with paradoxical bradycardia (Ref).

Dosage form information: Atropen auto-injector has been discontinued in the United States for >1 year.

Atrioventricular block, symptomatic and/or hemodynamically unstable

Atrioventricular block, symptomatic and/or hemodynamically unstable (off-label use):

Note: Not recommended for atrioventricular block below the atrioventricular node; sinus rate may increase but atrioventricular conduction may worsen. Only consider using in patients with second-degree or third-degree atrioventricular block occurring at the atrioventricular nodal level as a temporizing measure until a permanent pacemaker can be placed, if clinically indicated. In most cases, pharmacologic agents will not be effective and temporary transcutaneous or transvenous pacing is necessary as a bridge to permanent pacemaker placement. Atropine may not be effective and may cause paradoxical heart block or sinus arrest in heart transplant recipients who remain denervated (Ref).

IV, IM: 1 mg every 3 to 5 minutes as needed until symptoms resolve or heart rate is stabilized; maximum total dose: 3 mg (Ref).

Bradycardia during neuromuscular blockade reversal

Bradycardia during neuromuscular blockade reversal: IV: 5 to 7 mcg/kg when administered with edrophonium or 15 to 20 mcg/kg when administered with neostigmine (Ref).

Bradycardia, symptomatic and/or hemodynamically unstable

Bradycardia, symptomatic and/or hemodynamically unstable:

Note: Atropine may not be effective and may cause paradoxical heart block or sinus arrest in heart transplant recipients who remain denervated. Atropine may not be effective for type II second-degree or third-degree heart block (Ref).

IV, intraosseous, IM: 1 mg every 3 to 5 minutes as needed until symptoms resolve or heart rate is stabilized; maximum total dose: 3 mg (Ref).

Endotracheal (least preferred route): 2 to 2.5 mg every 3 to 5 minutes (Ref).

Inhibit salivation and secretions

Inhibit salivation and secretions (preanesthesia): IM, IV, SUBQ: 0.5 to 1 mg 30 to 60 minutes before procedure; repeat every 4 to 6 hours as needed; maximum total dose: 3 mg.

Muscarine-containing mushroom poisoning

Muscarine-containing mushroom poisoning (off-label dose): IV: 1 to 2 mg; titrate and repeat as needed to reverse symptoms (ie, titrate to achieve decreased bronchial secretions) (Ref).

Organophosphate or carbamate insecticide or nerve agent poisoning

Organophosphate or carbamate insecticide or nerve agent poisoning:

Note: The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; ≥2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous IV infusion in patients requiring large doses of atropine (Ref). Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is an essential component of the management of organophosphate insecticide and nerve agent toxicity; refer to Pralidoxime monograph for the specific route and dose.

IV:

Mild to moderate symptoms: Initial: 1 to 2 mg bolus (Ref); repeat by doubling the dose every 3 to 5 minutes if previous dose did not induce a response (Ref). Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (Ref). After the desired response is achieved with bolus dosing, consider starting an IV continuous infusion for improved clinical outcomes (Ref).

Severe symptoms: Initial: 3 to 5 mg bolus (Ref); repeat by doubling the dose every 3 to 5 minutes if previous dose did not induce a response (Ref). Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (Ref). After the desired response is achieved with bolus dosing, consider starting an IV continuous infusion for improved clinical outcomes (Ref).

IV continuous infusion: After desired response is achieved with IV boluses, administer 10% to 20% of the total cumulative IV bolus dose as an IV continuous infusion per hour (eg, if 18 mg given by IV bolus is required to achieve the desired response, start an IV continuous infusion of 1.8 mg per hour); adjust infusion rate as needed to maintain adequate response without causing atropine toxicity (Ref).

IM (AtroPen):

Mild symptoms (≥2 mild symptoms): Administer 2 mg as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld.

Severe symptoms (≥1 severe symptoms): Immediately administer three 2 mg doses in rapid succession.

Symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling, to guide therapy:

Mild symptoms: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.

Severe symptoms: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary).

Endotracheal: Usual dose: 2 to 2.5 times IV dose diluted in 5 to 10 mL of 0.9% sodium chloride or sterile water (Ref).

Stress echocardiography

Stress echocardiography (adjunctive agent) (diagnostic agent) (off-label use): IV: 0.25 to 0.5 mg every 1 minute as needed until 85% of age-predicted maximum heart rate is achieved; maximum total dose: 1 to 2 mg (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Atropine (systemic): Pediatric drug information")

Dosage guidance:

Dosage form information: Atropen auto-injector has been discontinued in the United States for >1 year.

Bradycardia

Bradycardia:

Infants, Children, and Adolescents:

IV, Intraosseous: 0.02 mg/kg/dose; minimum dose: 0.1 mg/dose, maximum dose: 0.5 mg/dose; may repeat once in 5 minutes; reserve use for those patients unresponsive to improved oxygenation and epinephrine (Ref); some have suggested the minimum dose should not be used in patients <5 kg (Ref).

Endotracheal: 0.04 to 0.06 mg/kg/dose; may repeat once if needed (Ref).

Inhibit salivation and secretions

Inhibit salivation and secretions (preoperative/intraoperative):

Infants and Children <12 years: IM, IV, SUBQ: 0.02 mg/kg/dose; maximum dose: 0.5 mg/dose; administer first dose 30 to 60 minutes preoperatively and then repeat every 4 to 6 hours as needed; maximum total dose: 1 mg/procedure.

Children ≥12 years and Adolescents: IM, IV, SUBQ: 0.02 mg/kg/dose; maximum dose: 1 mg/dose; administer first dose 30 to 60 minutes preoperatively and then repeat every 4 to 6 hours as needed; maximum total dose: 2 mg/procedure.

Intubation; emergent

Intubation; emergent (premedication): Note: Routine use not recommended for preintubation in infants and children; atropine may be considered in situations with a high-risk of bradycardia (eg, succinylcholine use) (Ref) or septic shock (Ref).

Infants and Children: IV: 0.02 mg/kg/dose with no minimum dose; maximum dose: 0.5 mg/dose (Ref).

Muscarine-containing mushroom poisoning

Muscarine-containing mushroom poisoning: Limited data available: Infants, Children, and Adolescents: IV: 0.02 mg/kg/dose; minimum dose: 0.1 mg. Titrate and repeat as needed to reverse symptoms (ie, titrate to achieve decreased bronchial secretions) (Ref).

Organophosphate or carbamate insecticide or nerve agent poisoning

Organophosphate or carbamate insecticide or nerve agent poisoning:

Note: If exposure is known or suspected, antidotal therapy should be given as soon as symptoms appear; do not wait for confirmation. The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; ≥2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous IV infusion in patients requiring large doses of atropine (Ref). Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to pralidoxime for the specific route and dose.

IV, IM, Intraosseous (Ref):

Infants and Children: Initial: 0.05 to 0.1 mg/kg; repeat every 3 to 5 minutes as needed, double the dose if previous dose does not induce atropinization (Ref). Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (Ref).

Adolescents: Initial: 1 to 3 mg; repeat every 3 to 5 minutes as needed, doubling the dose if previous dose does not induce atropinization. Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (Ref).

Continuous IV infusion: Infants, Children, and Adolescents: Following atropinization, administer 10% to 20% of the total loading dose required to induce atropinization as a continuous IV infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity (Ref).

IM (AtroPen): Infants, Children, and Adolescents: Number of doses dependent upon symptom severity:

Weight-directed dosing:

<7 kg (<15 lb): 0.25 mg/dose (yellow pen).

7 to 18 kg (15 to 40 lb): 0.5 mg/dose (blue pen).

>18 to 41 kg (>40 to 90 lb): 1 mg/dose (dark red pen).

>41 kg (>90 lb): 2 mg/dose (green pen).

Mild symptoms (≥2 mild symptoms): Administer the weight-directed dose listed above as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.

Severe symptoms (≥1 severe symptom): Immediately administer three weight-directed doses in rapid succession (Ref). Severe symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary); Note: Infants may become drowsy or unconscious with muscle floppiness as opposed to muscle twitching.

Endotracheal: Infants, Children, and Adolescents: Increase the dose by 2 to 3 times the usual IV dose. Mix with 3 to 5 mL of normal saline and administer. Flush with 3 to 5 mL of NS and follow with 5 assisted manual ventilations (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined. Severity and frequency of adverse reactions are dose related.

Cardiovascular: Asystole, atrial arrhythmia, atrial fibrillation, atrioventricular dissociation (transient), bigeminy, bradycardia, chest pain, decreased blood pressure, ECG changes (prolonged P wave, shortened PR segment, R on T phenomenon, shortened RT duration, prolonged QT interval, widening of QRS Complex, flattened T wave, repolarization abnormalities, ST segment elevation, retrograde conduction), ectopic beats (atrial), extrasystoles (nodal, ventricular, supraventricular), flushing, increased blood pressure, left heart failure, myocardial infarction, nodal arrhythmia (no P wave on ECG), palpitations, sinus tachycardia, supraventricular tachycardia (including junctional tachycardia), tachycardia, trigeminy, ventricular arrhythmia (including flutter), ventricular fibrillation, ventricular flutter, ventricular premature contractions, ventricular tachycardia, weak pulse (or impalpable peripheral pulses)

Central nervous system: Abnormal electroencephalogram (runs of alpha waves, increase in photic stimulation, and signs of drowsiness), agitation (children), amnesia, anxiety, ataxia, behavioral changes, coma, confusion, decreased deep tendon reflex, delirium, dizziness, drowsiness, dysarthria, dysmetria, emotional disturbance, excitement, feeling hot, hallucination (visual or aural), headache, hyperpyrexia, hyperreflexia, hypertonia, insomnia, intoxicated feeling, irritability (children), lack of concentration, lethargy (children), mania, myoclonus, neurologic abnormality, nocturnal enuresis, opisthotonus, paranoia, positive Babinski sign, restlessness, seizure (generally tonic-clonic), stupor, vertigo

Dermatologic: Anhidrosis, cold skin, dermatitis, dry and hot skin, erythematous rash, hyperhidrosis, macular eruption, maculopapular rash, papular rash, scarlatiniform rash, skin rash

Endocrine & metabolic: Dehydration, hyperglycemia, hypoglycemia, hypokalemia, hyponatremia, increased thirst, loss of libido

Gastrointestinal: Abdominal and bladder distension, abdominal pain, constipation, delayed gastric emptying, diminished bowel sounds, dry mucous membranes, dysphagia, malabsorption, nausea, oral lesion, paralytic ileus, salivation, vomiting, xerostomia

Genitourinary: Difficulty in micturition, impotence, urinary hesitancy, urinary retention, urinary urgency

Hematologic & oncologic: Abnormal erythrocytes (increased), decreased hemoglobin, increased hemoglobin, leukocytosis, petechiae

Hypersensitivity: Hypersensitivity reaction

Local: Injection site reaction

Neuromuscular & skeletal: Laryngospasm, muscle twitching, weakness

Ophthalmic: Abnormal eye movements (cyclophoria and heterophoria), angle-closure glaucoma (acute), blepharitis, blindness, blurred vision, conjunctivitis, crusted of eyelid, cycloplegia, decreased accommodation, decreased visual acuity, dry eye syndrome, eye irritation, lacrimation, mydriasis, photophobia, strabismus

Renal: Increased blood urea nitrogen

Respiratory: Bradypnea, changes in respiration (labored respiration), cyanosis, dyspnea, laryngitis, pulmonary edema, respiratory failure, stridor (inspiratory), tachypnea

Miscellaneous: Failure to thrive, fever (secondary to decreased sweat gland activity), swelling (children)

Contraindications

There are no contraindications listed in the manufacturer’s US labeling.

Canadian labeling: Hypersensitivity to atropine or any component of the formulation; GI obstruction, glaucoma (known or suspected), pyloric stenosis or prostatic hypertrophy (except in doses typically used for preanesthesia).

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity reactions, including anaphylactic reactions, may occur.

• Hyperthermia: Atropine may inhibit sweating and possibly lead to heat-related injury or hyperthermia in patients exposed to warm environments or exercise.

• Psychosis: Can occur in sensitive individuals or following use of excessive doses.

Disease-related concerns:

• Arrhythmias: Avoid relying on atropine for effective treatment of type II second-degree or third-degree AV block (with or without a new wide QRS complex). Asystole or bradycardic PEA: Although no evidence exists for significant detrimental effects, routine use is unlikely to have a therapeutic benefit and is no longer recommended (ACLS 2010).

• Cardiovascular disease: Use with caution in patients with myocardial ischemia, heart failure, tachyarrhythmias (including sinus tachycardia), and/or hypertension; treatment-related blood pressure increases and tachycardia may lead to ischemia, precipitate an MI, or increase arrhythmogenic potential.

• Chronic lung disease: Use with caution in patients with chronic lung disease; may cause thickening of bronchial secretions and formation of dangerous viscid plugs.

• Glaucoma: Use with caution in patients with severe narrow-angle glaucoma; may precipitate acute glaucoma.

• Hepatic impairment: Use with caution in patients with hepatic impairment; effects of atropine may be prolonged in severe hepatic impairment.

• Hiatal hernia: Use with caution in patients with hiatal hernia associated with reflux esophagitis.

• Hyperthyroidism: Use with caution in patients with hyperthyroidism.

• Myasthenia gravis: Use with extreme caution when used to treat side effects of acetylcholinesterase inhibition or avoid; may precipitate a myasthenic crisis.

• Neuropathy: Use with caution in patients with autonomic neuropathy.

• Pyloric stenosis: Use with caution in patients with partial pyloric stenosis; may cause complete pyloric obstruction.

• Renal impairment: Use with caution in patients with renal impairment; effects of atropine may be prolonged in severe renal impairment.

• Urinary retention: Use with caution in patients with urinary obstruction; may cause urinary retention.

Special populations:

• Heart transplant recipients: Atropine will likely be ineffective in treatment of bradycardia due to lack of vagal innervation of the transplanted heart. Cholinergic reinnervation may occur over time (years), so atropine may be used cautiously; however, some may experience paradoxical slowing of the heart rate and high-degree AV block upon administration (ACLS 2010; Bernheim 2004).

• Pediatric: Children may be more sensitive to the anticholinergic effects of atropine. Use with caution in children with spastic paralysis.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

Other warnings/precautions:

• Appropriate use: Anticholinesterase poisoning: Atropine reverses the muscarinic but not the nicotinic effects associated with anticholinesterase toxicity. Clinical symptoms consistent with highly-suspected organophosphate or carbamate insecticides or nerve agent poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests. Signs of atropinization include flushing, mydriasis, tachycardia, and dryness of the mouth or nose. Monitor effects closely when administering subsequent injections as necessary. The presence of these effects is not indicative of the success of therapy; inappropriate use of mydriasis as an indicator of successful treatment has resulted in atropine toxicity. Reversal of bronchial secretions is the preferred indicator of success. Adjunct treatment with a cholinesterase reactivator (eg, pralidoxime) may be required in patients with toxicity secondary to organophosphorus insecticides or nerve agents. Treatment should always include proper evacuation and decontamination procedures; medical personnel should protect themselves from inadvertent contamination. Antidotal administration is intended only for initial management; definitive and more extensive medical care is required following administration. Individuals should not rely solely on antidote for treatment, as other supportive measures (eg, artificial respiration) may still be required.

Warnings: Additional Pediatric Considerations

Several reports in the literature have described neonates developing central anticholinergic syndrome after receiving atropine for bradycardia at doses of 0.1 mg, the minimum dose that has been described for preventing paradoxical bradycardia. When evaluated based on weight, this dose exceeded 0.02 mg/kg in all cases (Gillick 1974; Prakash 2017; Rizzi 2004); some literature has recommended against using a minimum dose in patients <5 kg to prevent overdose (Barrington 2011; Prakash 2017).

Product Availability

Atropen auto-injector has been discontinued in the United States for >1 year.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection, as sulfate:

Generic: 8 mg/20 mL (20 mL)

Solution, Injection, as sulfate [preservative free]:

Generic: 0.4 mg/mL (1 mL [DSC]); 1 mg/mL (1 mL [DSC])

Solution, Intravenous, as sulfate [preservative free]:

Generic: 0.4 mg/mL (1 mL); 1 mg/mL (1 mL)

Solution Auto-injector, Intramuscular, as sulfate:

AtroPen: 0.5 mg/0.7 mL (0.7 mL [DSC]); 1 mg/0.7 mL (0.7 mL [DSC]); 2 mg/0.7 mL (0.7 mL [DSC]) [pyrogen free; contains phenol]

Solution Auto-injector, Intramuscular, as sulfate [preservative free]:

AtroPen: 0.25 mg/0.3 mL (0.3 mL [DSC]) [pyrogen free]

Solution Prefilled Syringe, Injection, as sulfate:

Generic: 1 mg/10 mL (10 mL)

Solution Prefilled Syringe, Injection, as sulfate [preservative free]:

Generic: 0.25 mg/5 mL (5 mL); 0.5 mg/5 mL (5 mL); 1 mg/10 mL (10 mL)

Generic Equivalent Available: US

May be product dependent

Pricing: US

Solution (Atropine Sulfate Injection)

8 mg/20 mL (per mL): $2.11 - $4.58

Solution (Atropine Sulfate Intravenous)

0.4 mg/mL (per mL): $13.48 - $14.50

1 mg/mL (per mL): $20.35 - $22.61

Solution Prefilled Syringe (Atropine Sulfate Injection)

0.25 mg/5 mL (per mL): $6.51

0.5 mg/5 mL (per mL): $2.29 - $4.26

1 mg/10 mL (per mL): $1.20 - $2.22

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection:

Generic: 0.6 mg/mL (1 mL)

Solution, Injection, as sulfate:

Generic: 0.1 mg/mL (10 mL); 0.4 mg/mL (1 mL, 10 mL)

Solution Prefilled Syringe, Injection:

Generic: 0.5 mg/5 mL (5 mL); 1 mg/5 mL (5 mL)

Solution Prefilled Syringe, Injection, as sulfate:

Generic: 0.5 mg/5 mL ([DSC])

Prescribing and Access Restrictions

The AtroPen formulation is available for use primarily by the Department of Defense.

Administration: Adult

IM: AtroPen: Administer to the outer thigh. Firmly grasp the autoinjector with the green tip (0.5 mg, 1 mg, and 2 mg autoinjector) or black tip (0.25 mg autoinjector) pointed down; remove the yellow safety release (0.5 mg, 1 mg, and 2 mg autoinjector) or gray safety release (0.25 autoinjector). Jab the green tip at a 90° angle against the outer thigh; may be administered through clothing as long as pockets at the injection site are empty. In thin patients, bunch up the thigh prior to injection. Hold the autoinjector in place for 10 seconds following the injection; remove the autoinjector and massage the injection site. After administration, the needle will be visible; if the needle is not visible, repeat the above steps. After use, bend the needle against a hard surface (needle does not retract) to avoid accidental injury.

IV: Administer undiluted by rapid IV injection; slow injection may result in paradoxical bradycardia. In bradycardia, atropine administration should not delay treatment with external pacing.

Intraosseous (IO): May administer intraosseous if needed.

Endotracheal: Dilute in ≤10 mL NS or sterile water. Absorption may be greater with sterile water. Stop compressions (if using for cardiac arrest), spray the drug quickly down the tube. Follow immediately with several quick insufflations and continue chest compressions.

SUBQ: May administer subcutaneous if needed.

Administration: Pediatric

Endotracheal: May administer dose undiluted, followed by flush with 1 to 5 mL of NS after endotracheal administration or may further dilute in NS or sterile water prior to administration (ie, 1 to 2 mg in ≤10 mL of NS or sterile water); follow with 5 assisted manual ventilations (Ref). If using for cardiac arrest, stop compressions during drug administration and resume chest compressions following manual ventilation.

Flush volume based on indication:

Bradycardia:

Neonates: Flush with ≥1 mL NS (Ref).

Infants, Children, and Adolescents: Flush with 5 mL NS (Ref).

Organophosphate or carbamate insecticide or nerve agent poisoning: Flush with 3 to 5 mL NS (Ref).

Parenteral:

IV: Administer undiluted by rapid IV injection; slow injection may result in paradoxical bradycardia.

IM: AtroPen: Administer to the outer thigh. Firmly grasp the autoinjector with the green tip (0.5 mg, 1 mg, and 2 mg autoinjector) or black tip (0.25 mg autoinjector) pointed down; remove the yellow safety release (0.5 mg, 1 mg, and 2 mg autoinjector) or gray safety release (0.25 autoinjector). Firmly jab the green tip at a 90° angle against the outer thigh; may be administered through clothing as long as pockets at the injection site are empty. In thin patients or patients <6.8 kg (15 lb), bunch up the thigh prior to injection. Hold the autoinjector in place for 10 seconds following the injection; remove the autoinjector and massage the injection site. After administration, the needle will be visible; if the needle is not visible, repeat the above steps with more pressure. After use, bend the needle against a hard surface (needle does not retract) to avoid accidental injury.

Use: Labeled Indications

Bradycardia during neuromuscular blockade reversal: Adjuvant use during neuromuscular blockade reversal with anticholinesterases (eg, edrophonium, neostigmine) to manage bradycardia.

Bradycardia, symptomatic: Treatment of symptomatic sinus bradycardia.

Inhibition of salivation and secretions (preanesthesia): Preoperative/preanesthetic medication to inhibit salivation and secretions.

Muscarine-containing mushroom poisoning: Treatment of symptoms from muscarine-containing mushroom poisoning.

Organophosphate or carbamate insecticide or nerve agent poisoning: Antidote for anticholinesterase poisoning (carbamate insecticides, nerve agents, organophosphate insecticides).

Use: Off-Label: Adult

Atrioventricular block, symptomatic and/or hemodynamically unstable; Stress echocardiography (adjunctive agent) (diagnostic agent)

Medication Safety Issues
Older Adult: High-Risk Medication:

Beers Criteria: Atropine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its highly anticholinergic properties and uncertain effectiveness as an antispasmodic (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Acetylcholinesterase Inhibitors. Risk C: Monitor

Aclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Acrivastine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Alpha1-Agonists: Atropine (Systemic) may increase hypertensive effects of Alpha1-Agonists. Risk C: Monitor

Amantadine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Amezinium: Atropine (Systemic) may increase stimulatory effects of Amezinium. Risk C: Monitor

Benperidol: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Benperidol. Risk C: Monitor

Benztropine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Benztropine. Risk C: Monitor

Beta-Acetyldigoxin: Atropine (Systemic) may increase serum concentration of Beta-Acetyldigoxin. Risk C: Monitor

Biperiden: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Biperiden. Risk C: Monitor

Bornaprine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Botulinum Toxin-Containing Products: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Bromperidol: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bromperidol. Risk C: Monitor

Buclizine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Buclizine. Risk C: Monitor

Cannabinoid-Containing Products: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of Cannabinoid-Containing Products. Risk C: Monitor

Chlorprothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Chlorprothixene. Risk C: Monitor

Cimetropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Cimetropium. Risk X: Avoid

CloZAPine: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider Therapy Modification

Cyclizine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Darifenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Darifenacin. Risk C: Monitor

Dicyclomine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dicyclomine. Risk C: Monitor

Dimethindene (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dimethindene (Systemic). Risk C: Monitor

DroNABinol: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of DroNABinol. Risk X: Avoid

Eluxadoline: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Eluxadoline. Risk X: Avoid

EPHEDrine (Systemic): Atropine (Systemic) may increase therapeutic effects of EPHEDrine (Systemic). Risk C: Monitor

Fesoterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Fesoterodine. Risk C: Monitor

FluPHENAZine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Gastrointestinal Agents (Prokinetic): Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Gastrointestinal Agents (Prokinetic). Risk C: Monitor

Gepotidacin: May decrease anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Glucagon: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor

Glycopyrrolate (Oral Inhalation): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Oral Inhalation). Risk X: Avoid

Glycopyrrolate (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Systemic). Risk C: Monitor

Glycopyrronium (Topical): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Ipratropium (Nasal): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ipratropium (Oral Inhalation): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Itopride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Itopride. Risk C: Monitor

Levosulpiride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Levosulpiride. Risk X: Avoid

Macimorelin: Coadministration of Atropine (Systemic) and Macimorelin may alter diagnostic results. Risk X: Avoid

Maprotiline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Maprotiline. Risk C: Monitor

Melperone: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Methotrimeprazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methotrimeprazine. Risk C: Monitor

Methscopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methscopolamine. Risk C: Monitor

Mirabegron: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Mirabegron. Risk C: Monitor

Nitroglycerin: Agents with Clinically Relevant Anticholinergic Effects may decrease absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor

OLANZapine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OLANZapine. Risk C: Monitor

Opioid Agonists: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor

Opipramol: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Oxatomide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

OxyBUTYnin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OxyBUTYnin. Risk C: Monitor

Perazine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Perphenazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Perphenazine. Risk C: Monitor

Potassium Chloride: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid

Potassium Citrate: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid

Pramlintide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. These effects are specific to the GI tract. Risk X: Avoid

Promethazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Promethazine. Risk C: Monitor

Propantheline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Propantheline. Risk C: Monitor

Propiverine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

QuiNIDine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ramosetron: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Ramosetron. Risk C: Monitor

Revefenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Revefenacin. Risk X: Avoid

Ritodrine: Atropine (Systemic) may increase adverse/toxic effects of Ritodrine. Risk C: Monitor

Rivastigmine: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Rivastigmine. Rivastigmine may decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider Therapy Modification

Scopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Scopolamine. Risk C: Monitor

Secretin: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider Therapy Modification

Sincalide: Drugs that Affect Gallbladder Function may decrease therapeutic effects of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider Therapy Modification

Sofpironium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Sofpironium. Risk X: Avoid

Thiazide and Thiazide-Like Diuretics: Agents with Clinically Relevant Anticholinergic Effects may increase serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Thiothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Thiothixene. Risk C: Monitor

Tiapride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Tiapride. Risk C: Monitor

Tiotropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tiotropium. Risk X: Avoid

Tolterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tolterodine. Risk C: Monitor

Topiramate: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Topiramate. Risk C: Monitor

Tricyclic Antidepressants: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tricyclic Antidepressants. Risk C: Monitor

Trimethobenzamide: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trimethobenzamide. Risk C: Monitor

Trospium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trospium. Risk C: Monitor

Umeclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Zuclopenthixol: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Zuclopenthixol. Risk C: Monitor

Pregnancy Considerations

Atropine crosses the placenta.

In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).

Breastfeeding Considerations

Atropine is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.

Monitoring Parameters

Heart rate, blood pressure, pulse, mental status; intravenous administration requires a cardiac monitor

Organophosphate or carbamate insecticide or nerve agent poisoning: Heart rate, blood pressure, respiratory status, oxygenation secretions. Maintain atropinization with repeated dosing as indicated by clinical status. Crackles in lung bases, or continuation of cholinergic signs, may be signs of inadequate dosing. Pulmonary improvement may not parallel other signs of atropinization. Monitor for signs and symptoms of atropine toxicity (eg, fever, muscle fasciculations, delirium); if toxicity occurs, discontinue atropine and monitor closely.

Consult individual institutional policies and procedures.

Mechanism of Action

Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; increases cardiac output, dries secretions. Atropine reverses the muscarinic effects of cholinergic poisoning due to agents with acetylcholinesterase inhibitor activity by acting as a competitive antagonist of acetylcholine at muscarinic receptors. The primary goal in cholinergic poisonings is reversal of bronchorrhea and bronchoconstriction. Atropine has no effect on the nicotinic receptors responsible for muscle weakness, fasciculations, and paralysis; concurrent administration of pralidoxime is necessary to reverse the nicotinic effects associated with organophosphate insecticide or nerve agent toxicity.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action:

Inhibition of salivation: IM: Within 30 minutes; maximum effect: 30 to 60 minutes (Mirakhur 1980; Volz-Zang 1995)

Increased heart rate:

IM: Within 15 to 30 minutes (Kentala 1990; Volz-Zang 1995); maximum effect: 45 to 60 minutes (Mirakhur 1980; Volz-Zang 1995)

IV: Immediate; maximum effect: 0.7 to 4 minutes (Lonnerholm 1975; Santini 1999)

Duration: Inhibition of salivation: IM: ≤4 hours (Mirakhur 1980; Volz-Zang 1995)

Absorption: Rapid and well absorbed from all dosage forms

Distribution: Widely throughout the body; crosses blood-brain barrier

Protein binding: 14% to 44%

Metabolism: Hepatic via enzymatic hydrolysis

Half-life elimination: Children <2 years: 6.9 ± 3 hours; Children >2 years: 2.5 ± 1.2 hours; Adults: 3 ± 0.9 hours; Elderly 65 to 75 years of age: 10 ± 7.3 hours

Time to peak: IM: 30 minutes; IM autoinjector: 3 minutes

Excretion: Urine (13% to 50% as unchanged drug and metabolites)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Older adult: Elimination half-life is more than doubled.

Sex: AUC and Cmax are 15% higher in females than males; Elimination half-life is ~20 minutes shorter in females than males.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AR) Argentina: Endotropina | Sulfato de atropina Norgreen;
  • (AT) Austria: Atropinsulfat Aguettant;
  • (AU) Australia: Atropine sulphate;
  • (BE) Belgium: Atropine sulfate aguettant;
  • (BR) Brazil: Sulfato de atropina;
  • (CH) Switzerland: Atropin sulfat | Atropin sulfat aguettant | Atropinium sulfuricum streuli;
  • (CN) China: Atropine;
  • (CZ) Czech Republic: Atropin | Atropine accord;
  • (DE) Germany: Atropin accord | Dysurgal | Min-i-jet atropine;
  • (ET) Ethiopia: Atropine sulphate;
  • (FI) Finland: Atropin | Atropin aguettant | Atropin stragen | Atropine accord;
  • (FR) France: Atropine sulfate aguettant;
  • (GB) United Kingdom: Atropine sulphate;
  • (HK) Hong Kong: Atropine;
  • (HU) Hungary: Atropinum sulfuricum;
  • (ID) Indonesia: Atropine;
  • (IE) Ireland: Atropine sulfate aguettant | Atropine sulphate;
  • (IL) Israel: Atropine;
  • (IN) India: Atropine | Atropine sulphate | Atrothem;
  • (IT) Italy: Atropina solfato laboratoire aguettant;
  • (JP) Japan: Atquick | Atropine;
  • (KE) Kenya: Atropine;
  • (KR) Korea, Republic of: Sergal;
  • (KW) Kuwait: Atropine sulfate aguettant;
  • (LT) Lithuania: Atropin | Dysurgal;
  • (LV) Latvia: Atropin;
  • (MX) Mexico: Amixteria;
  • (MY) Malaysia: Atropine sulphate;
  • (NL) Netherlands: Atropine sulf | Atropinesulf | Atropinesulfaat Aguettant;
  • (NO) Norway: Atropin | Atropin aguettant | Atropin stragen;
  • (NZ) New Zealand: Atropine sulphate;
  • (PK) Pakistan: Atroject | Atropine;
  • (PL) Poland: Atropin;
  • (PR) Puerto Rico: Sal-tropine;
  • (PT) Portugal: Atropina accord | Atropina aguettant | Atropina Labesfal;
  • (PY) Paraguay: Atropina sulfato lasca;
  • (RO) Romania: Sulfat de atropina accord;
  • (RU) Russian Federation: Atropin | Atropine nova;
  • (SA) Saudi Arabia: Atropine sulphate;
  • (SE) Sweden: Atropin stragen | Atropine accord;
  • (SG) Singapore: Atropine | Atropine sulphate;
  • (SI) Slovenia: Atropina solfato monico | Atropini sulfas;
  • (SK) Slovakia: Atropin;
  • (TH) Thailand: Atropine;
  • (TW) Taiwan: Atropin sulfate | Atropine | Bellaton | Soreless | Spanton | Spasmatal;
  • (UA) Ukraine: Atropin sulfate;
  • (UG) Uganda: Atropine sulfate aguettant;
  • (UY) Uruguay: Endotropina;
  • (ZW) Zimbabwe: Atropine sulphate | Atropine sulphate fresenius | Pharma q atropine
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Abedin MJ, Sayeed AA, Basher A, Maude RJ, Hoque G, Faiz MA. Open-label randomized clinical trial of atropine bolus injection versus incremental boluses plus infusion for organophosphate poisoning in Bangladesh. J Med Toxicol. 2012;8(2):108-117. doi:10.1007/s13181-012-0214-6 [PubMed 22351300]
  3. Agency for Toxic Substances and Disease Registry (ATSDR), “Nerve Agents,” 2011. Available at http://www.atsdr.cdc.gov/MHMI/mmg166.pdf
  4. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. doi: 10.1067/mpd.2001.116281. [PubMed 11487763]
  5. American Heart Association (AHA). 2015 Handbook of Emergency Cardiovascular Care (ECC) for Healthcare Providers. First American Heart Association Printing. November 2015.
  6. American Heart Association (AHA). CPR & First Aid: Emergency Cardiovascular Care. Adult Bradycardia Algorithm. https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/algorithms. Published 2020. Accessed January 29, 2021.
  7. Andriessen P, Janssen BJ, Berendsen RC, et al. Cardiovascular autonomic regulation in preterm infants: the effect of atropine. Pediatr Res. 2004; 56(6):939-946. [PubMed 15470200]
  8. Atropen (atropine) [prescribing information]. St. Louis, MO: Meridian Medical Technologies Inc; September 2022.
  9. Atropine Ansyr syringe and Lifeshield Abboject syringe [prescribing information]. Lake Forest, IL: Hospira Inc; July 2020.
  10. Atropine single-dose vials [prescribing information]. Shirley, NY: American Regent Inc; September 2021.
  11. Atropine multi-dose vials [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; December 2021.
  12. Atropine sulfate injection [prescribing information]. S El Monte, CA: International Medication Systems, Limited; February 2021.
  13. Atropine sulfate injection 0.1 mg [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; October 2022.
  14. Atropine sulfate injection prefilled syringes [product monograph]. Montréal, Quebec, Canada: Aguettant Canada Inc; November 2021.
  15. Atropine sulfate solution [product monograph]. Mississauga, Ontario, Canada: Hikma Canada Limited; April 2022.
  16. Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? Birth Defects Res A Clin Mol Teratol. 2003;67(2):133-140. [PubMed 12769509]
  17. Barrington KJ, "The Myth of a Minimum Dose for Atropine," Pediatrics, 2011, 127(4):783-4. [PubMed 21382950]
  18. Bernheim A, Fatio R, Kiowski W, et al, “Atropine Often Results in Complete Atrioventricular Block or Sinus Arrest After Cardiac Transplantation: An Unpredictable and Dose-Independent Phenomenon,” Transplantation, 2004, 77(8):1181-5. [PubMed 15114081]
  19. Bholasingh R, Cornel JH, Kamp O, et al. Prognostic value of predischarge dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. J Am Coll Cardiol. 2003;41(4):596-602. [PubMed 12598071]
  20. Boudet J, Qing W, Boyer-Chammard A, Del Franco G, Bergougnan JL, Rosen P, Meyer P. Dose-response effects of atropine in human volunteers. Fundam Clin Pharmacol. 1991;5(7):635-640. [PubMed 1778541]
  21. Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666-688. [PubMed 19325359]
  22. Camarozano AC, Siqueira-Filho AG, Weitzel LH, Resende P, Noé RA. The effects of early administration of atropine during dobutamine stress echocardiography: advantages and disadvantages of early dobutamine-atropine protocol. Cardiovasc Ultrasound. 2006;4:17. doi:10.1186/1476-7120-4-17 [PubMed 16569248]
  23. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm. [PubMed 6810084]
  24. Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. Anesthesiology. 1982;57(4):261-266. [PubMed 7125261]
  25. Dart RC, Borron SW, Caravati EM, et al; Antidote Summit Authorship Group. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2009;54(3):386-394.e1. doi:10.1016/j.annemergmed.2009.01.023 [PubMed 19406507]
  26. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
  27. de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care (Reprint). Pediatrics. 2015;136(Suppl 2:)S176-195. [PubMed 26471384]
  28. Dempsey EM, Al Hazzani F, Faucher D, et al. Facilitation of neonatal endotracheal intubation with mivacurium and fentanyl in the neonatal intensive care unit. Arch Dis Child Fetal Neonatal Ed. 2006; 91(4):F279-282. [PubMed 16464937]
  29. Dix J, Weber RJ, Frye RF, et al. Stability of atropine sulfate prepared for mass chemical terrorism. J Toxicol Clin Toxicol. 2003;41(6):771-775. [PubMed 14677786]
  30. Eddleston M, Buckley NA, Checketts H, et al. Speed of initial atropinisation in significant organophosphorus pesticide poisoning - a systematic comparison of recommended regimens. J Toxicol Clin Toxicol. 2004a;42(6):865-875. [PubMed 15533026]
  31. Eddleston M, Dawson A, Karalliedde L, et al. Early management after self-poisoning with an organophosphorus or carbamate pesticide – a treatment protocol for junior doctors. Crit Care. 2004b;8(6):R391-R397. [PubMed 15566582]
  32. Eichenwald EC, ed. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
  33. Eisenberg MS and Mengert TJ, “Cardiac Resuscitation,” N Engl J Med, 2001, 344(17):1304-13. [PubMed 11320390]
  34. Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(suppl 3):640-656.
  35. Fioretti PM, Poldermans D, Salustri A, Forster T, Bellotti P, Boersma E, McNeill AJ, el-Said ES, Roelandt JR. Atropine increases the accuracy of dobutamine stress echocardiography in patients taking beta-blockers. Eur Heart J. 1994;15(3):355-360. [PubMed 8013509]
  36. Gillick JS. Atropine toxicity in a neonate. Br J Anaesth. 1974;46(10):793-794. [PubMed 4621205]
  37. Goldfrank LR. Mushrooms. Goldfrank's Toxicologic Emergencies. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. New York, NY: McGraw Hill, Inc; 2019;1581-1596.
  38. Gropper M, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Leslie K, eds. Miller's Anesthesia, Volume 1 and 2. 9th ed. Elsevier; 2019.
  39. Hazinski MF, Shuster M, Donnino MW, et al. 2015 Handbook of Emergency Cardiovascular Care for Healthcare Providers. South Deerfield, MA: American Heart Association; 2015.
  40. Hegenbarth MA, “Preparing for Pediatric Emergencies: Drugs to Consider,” Pediatrics, 2008, 121(2):433-43. [PubMed 18245435]
  41. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016;23(3):606-639. doi:10.1007/s12350-015-0387-x [PubMed 26914678]
  42. Howland MA. Antidotes in depth – Atropine. Goldfrank's Toxicologic Emergencies. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. New York, NY: McGraw Hill, Inc; 2018;1503-1507.
  43. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  44. Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. Circulation. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300. [PubMed 26443610]
  45. Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics. 2010;126(5):e1400-1413. [PubMed 20956432]
  46. Kentala E, Kaila T, Iisalo E, Kanto J. Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. Int J Clin Pharmacol Ther Toxicol. 1990;28(9):399-404. [PubMed 2228327]
  47. King AM, Aaron CK. Organophosphate and carbamate poisoning. Emerg Med Clin North Am. 2015;33(1):133-151. [PubMed 25455666]
  48. Kleinman ME, Chameides L, Schexnayder SM, et al, “Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122(18 Suppl 3):876-908. [PubMed 20956230]
  49. Kumar P, Denson SE, Mancuso TJ, et al. Premedication for nonemergency endotracheal intubation in the neonate. Pediatrics. 2010; 125(3):608-615.
  50. Kumar SS, Jain N, Prakash S, Pawar M. Central anticholinergic syndrome in a neonate operated for tracheoesophageal fistula. Indian J Anaesth. 2015;59(5):330-331. [PubMed 26019366]
  51. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(7):e51-e156. doi:10.1016/j.jacc.2018.10.044 [PubMed 30412709]
  52. Ling LH, Pellikka PA, Mahoney DW, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. J Am Coll Cardiol. 1996;28(3):551-557. doi:10.1016/0735-1097(96)00195-7 [PubMed 8772738]
  53. Lonnerholm G, Widerlöv E. Effect of intravenous atropine and methylatropine on heart rate and secretion of saliva in man. Eur J Clin Pharmacol. 1975;8(3-4):233-240. [PubMed 786681]
  54. McNeill AJ, Fioretti PM, el-Said SM, Salustri A, Forster T, Roelandt JR. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol. 1992;70(1):41-46. [PubMed 1615868]
  55. Mirakhur RK, Dundee JW. Comparison of the effects of atropine and glycopyrrolate on various end-organs. J R Soc Med. 1980;73(10):727-730. [PubMed 7241426]
  56. Mirakhur RK, Dundee JW, Jones CJ, Coppel DL, Clarke RS. Reversal of neuromuscular blockade: dose determination studies with atropine and glycopyrrolate given before or in a mixture with neostigmine. Anesth Analg. 1981;60(8):557-562. [PubMed 7196168]
  57. Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” Chest, 2003, 123(3):897-922. [PubMed 12628894]
  58. Naguib M, Gomaa M. Atropine-neostigmine mixture: a dose-response study. Can J Anaesth. 1989;36(4):412-417. [PubMed 2758540]
  59. Nelson WE, Behrman RE, Kliegman RM, et al, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.
  60. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S729-S767. doi:10.1161/CIRCULATIONAHA.110.970988 [PubMed 20956224]
  61. Neumar RW, Shuster M, Callaway CW, et al. Part 1: executive summary: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S315-S367. doi:10.1161/CIR.0000000000000252 [PubMed 26472989]
  62. Oei J, Hari R, Butha T, Lui K. Facilitation of neonatal nasotracheal intubation with premedication: a randomized controlled trial. J Paediatr Child Health. 2002;38(2):146-150. [PubMed 12030995]
  63. Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16 suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916 [PubMed 33081529]
  64. Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33(1):1-41.e8. doi:10.1016/j.echo.2019.07.001 [PubMed 31740370]
  65. Picano E, Mathias W Jr, Pingitore A, Bigi R, Previtali M. Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group. Lancet. 1994;344(8931):1190-1192. [PubMed 7934540]
  66. Prakash S, Mullick P. Is a minimum dose of atropine in children justified? J Anaesthesiol Clin Pharmacol. 2017;33(2):282-283. [PubMed 28781474]
  67. Refer to manufacturer's labeling.
  68. Reigart JR and Roberts JR, “Recognition and Management of Pesticide Poisonings,” U.S. Environmental Protection Agency, Washington, D.C., 5th edition, 1999: 34-47. Available at http://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm
  69. Rizzi RR, Ho J. Post resuscitation central anticholinergic syndrome. Resuscitation. 2004;61(1):101-102. [PubMed 15081189]
  70. Roberts DM and Aaron CK, “Management of Acute Organophosphorus Pesticide Poisoning,” BMJ, 2007, 334(7594):629-34. [PubMed 17379909]
  71. Roberts JR, Karr CJ, Council On Environmental Health. Pesticide exposure in children. Pediatrics. 2012;130(6):e1765-1788. [PubMed 23184105]
  72. Roberts JR, Reigart JR. Recognition and management of pesticide poisonings. 6th ed. United States Environmental Protection Agency. 2013. Available at https://www.epa.gov/sites/production/files/2015-01/documents/rmpp_6thed_final_lowresopt.pdf.
  73. Roberts KD, Leone TA, Edwards WH, et al. Premedication for nonemergent neonatal intubations: a randomized, controlled trial comparing atropine and fentanyl to atropine, fentanyl, and mivacurium. Pediatrics. 2006; 118(4):1583-1591. [PubMed 17015550]
  74. Rotenberg JS and Newmark J, "Nerve Agent Attacks on Children: Diagnosis and Management," Pediatrics, 2003, 112(3 Pt 1):648-58. [PubMed 12949297]
  75. Santini M, Ammirati F, Colivicchi F, Gentilucci G, Guido V. The effect of atropine in vasovagal syncope induced by head-up tilt testing. Eur Heart J. 1999;20(23):1745-1751. [PubMed 10562483]
  76. Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. Pediatrics. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450 [PubMed 31871244]
  77. Stolbach A, Bebarta V, Beuhler M, et al. ACMT position statement: alternative or contingency countermeasures for acetylcholinesterase inhibiting agents. J Med Toxicol. 2018;14(3):261-263. doi:10.1007/s13181-018-0658-4 [PubMed 29667118]
  78. Stollings JL, Diedrich DA, Oyen LJ, Brown DR. Rapid-sequence intubation: a review of the process and considerations when choosing medications. Ann Pharmacother. 2014;48(1):62-76. [PubMed 24259635]
  79. Thiermann H, Worek F, Kehe K. Limitations and challenges in treatment of acute chemical warfare agent poisoning. Chem Biol Interact. 2013;206(3):435-443. doi:10.1016/j.cbi.2013.09.015 [PubMed 24091052]
  80. Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16 Suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901 [PubMed 33081526]
  81. US Food and Drug Administration (FDA). Search list of extended use dates to assist with drug shortages. https://www.fda.gov/drugs/drug-shortages/search-list-extended-use-dates-assist-drug-shortages. Published June 15, 2017. Accessed July 15, 2021. [PubMed 33081526]
  82. Volz-Zang C, Waldhäuser T, Schulte B, Palm D. Comparison of the effects of atropine in vivo and ex vivo (radioreceptor assay) after oral and intramuscular administration to man. Eur J Clin Pharmacol. 1995;49(1-2):45-49. [PubMed 8751020]
Topic 103444 Version 380.0